Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Drops 5-Scale CEA Rating, Pitches Slope-Like Price Adjustment Model: Chuikyo
October 5, 2017
- Chuikyo Mulls over Scope of CEA-Based Price Adjustments - Premium Portion or Total NHI Price?
October 5, 2017
- Payers Oppose Price Hikes based on CEA at 1st Joint Meeting: Chuikyo
October 5, 2017
- Chuikyo Members Object to Extension of Prescription Limit for Injectable Ethical Narcotic
October 5, 2017
- MHLW Wants to Introduce Conditional Early Approval System This Month: Minister
October 3, 2017
- MHLW Presents Four Patterns for Review of Clinical Research That Falls Under “Specified Clinical Research” Category
October 2, 2017
- Drug Makers to Be Required to Disclose Donations, Lecture Fees, and Writing Fees Tied to “Specified Clinical Research”
October 2, 2017
- MHLW to Compile Guidelines for Proper Drug Promotion Activities
October 2, 2017
- (Update) Bayer Told to Improve Practice over ADR Reporting Delays, Gets “Verbal Guidance” for Xarelto Survey Fuss
October 2, 2017
- MHLW Unveils Planned Framework for Conditional Early Approval Scheme
September 29, 2017
- Keytruda’s Sakigake Designation Revoked after Opdivo Gastric Cancer Nod
September 29, 2017
- MHLW OKs Japan’s 1st PD-L1 Inhibitor, 8-Week Hep C Med, Ibrance and More
September 28, 2017
- As Complaints of Shortages Grow for Japanese Encephalitis Vaccine, MHLW Plans Centralized Collection/Feedback of Supply-Demand Data for Distributers
September 27, 2017
- Trazenta, Amoxicillin and Others under PMDA Risk Review
September 26, 2017
- Interdepartmental Cooperation Needed to Treat Symptoms Following HPV Vaccination: MHLW Panels
September 26, 2017
- MHLW to Urge Drug Makers to Create Systems to Prevent Improper Promotional Activities: Official
September 25, 2017
- MHLW Panel Approves Increase in Raw Plasma Allocation to Nihon Pharmaceutical to 350,000 Liters
September 22, 2017
- Kaketsuken in Talks with “Several Entities” over Possible Biz Transfer: New Chief
September 21, 2017
- MHLW to Consider Use of New Comprehensive Test System to Promote Practical Use of Genomic Medicine for Cancer: Official
September 21, 2017
- MHLW Issues Notification on Drug Criteria for Optimal Use Guidelines
September 20, 2017
ページ
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…